## Edgar Filing: WILSON TROY EDWARD - Form 4

	)18 \							OMB A	PPROVAL		
FURI	<b>FORM 4</b> UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB			
if no lo subject Sectior	to SIATEN 16.	MENT OF CHANGES IN BENEFICIAL O SECURITIES					WNERSHIP OF	Expires: Estimated burden hou	urs per		
Form 4 Form 5 obligat may co <i>See</i> Ins 1(b).	Filed put	(a) of the	Public U	Jtility Hol	ding Co		ange Act of 1934, t of 1935 or Sectio 1940	response	. 0.5		
Print or Type	e Responses)										
				2. Issuer Name <b>and</b> Ticker or Trading Symbol Zosano Pharma Corp [ZSAN]			5. Relationship of Reporting Person(s) to Issuer				
(Last)					· -	(Check			k all applicable)		
C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT			(Month/Day/Year) 05/31/2018				X_ Director 10% Owner Officer (give title Other (specify below) below)				
(Street) 4. If Amendment, I Filed(Month/Day/Ye					-	al	<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>				
FREMON	T, CA 94555						Person	More than One R	eporung		
(City)	(State)	(Zip)	Tal	ole I - Non-I	Derivative	e Securities	Acquired, Disposed o	f, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) or l of (D) 4 and 5) (A) or	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: R	eport on a separate line	e for each c	lass of sec	urities benef	ficially ow	ned directly	or indirectly.				
					inforı requi	mation con red to resp ays a curre	spond to the collect tained in this form ond unless the for ontly valid OMB con	are not m	SEC 1474 (9-02)		
	Tah	le II - Deri	vative Se	curities Acq	uired, Di	sposed of, or	Beneficially Owned				

## Edgar Filing: WILSON TROY EDWARD - Form 4

	Security Instr. 3)	2				Acquired (A) or Disposed of (D) (Instr. 3, 4,	(Month/Day/Year) f		(Instr. 3 and 4)		(
					Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
(	Stock Option right to ouy)	\$ 4.24	05/31/2018 <u>(1)</u>		A	25,000	(2)	04/16/2028	Common Stock	25,000	
Reporting Owners											
Banauting Ourses Name / Addusse			Relatio	nships							

<b>Reporting Owner Name / Address</b>	Relationships					
1	Director	10% Owner	Officer	Other		
WILSON TROY EDWARD C/O ZOSANO PHARMA CORPORATION 34790 ARDENTECH COURT FREMONT, CA 94555	Х					
Signatures						
10/ Joffroy J. Quillon						

/s/ Jeffrey L. Quillen, 06/01/2018 attorney-in-fact

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option grant was approved by the compensation committee of the Company's board of directors on April 16, 2018, subject to(1) stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on May 31, 2018.
- (2) The shares underlying the stock option vest in equal monthly installments over a four-year period, beginning on May 16, 2018, so that all shares shall have vested on April 16, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

C